Current aspects of targeted therapy in head and neck tumors

European Archives of Oto-Rhino-Laryngology

Volumn 265, Issue SUPPL. 1, 2008, Pages

  Dietz, Andreas ^a   Boehm, Andreas ^a   Mozet, Christian ^a   Wichmann, Gunnar ^a   Giannis, Athanassios ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cetuximab; EGFR targeting; Head and neck tumors; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

ADVEXIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ENZASTAURIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; LAPATINIB; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; PELITINIB; PEMETREXED; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAE 226; TAE 266; TRASTUZUMAB; VANDETANIB;

ACNEIFORM RASH; ANGIOGENESIS; APOPTOSIS; ASPIRATION; BACTEREMIA; BINDING AFFINITY; BLOOD TOXICITY; BREAST CANCER; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CYTOTOXICITY; DIARRHEA; DISEASE SEVERITY; DIVERTICULITIS; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FIBROSIS; HEAD AND NECK CARCINOMA; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; KIDNEY CANCER; LARYNX DISORDER; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DERMATITIS; RASH; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMACH PERFORATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 47349117201     PISSN: 09374477     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00405-008-0697-6     Document Type: Conference Paper

References (63)

1. Steiner W, Ambrosch P, Hess CF, Kron M (2001) Organ preservation by transoral laser microsurgery in piriform sinus carcinoma. Otolaryngol Head Neck Surg 124(1):58-67
2. Snyderman CH, Kassam AB (2006) Endoscopic techniques for pathology of the anterior cranial fossa and ventral skull base. J Am Coll Surg 202(3):563
3. Ferlito A, Rinaldo A, Silver CE, Shah JP, Suárez C, Medina JE, Kowalski LP, Johnson JT, Strome M, Rodrigo JP, Werner JA, Takes RP, Towpik E, Robbins KT, Leemans CR, Herranz J, Gavilán J, Shaha AR, Wei WI (2006) Neck dissection: then and now. Auris Nasus Larynx 33(4):365-374
4. Strauss G, Koulechov K, Röttger S, Bahner J, Trantakis C, Hofer M, Korb W, Burgert O, Meixensberger J, Manzey D, Dietz A, Lüth T (2006) Clinical efficiency and the influence of human factors on ear, nose, and throat navigation systems. HNO 54(12):947-957
5. Trotti A, Bentzen SM (2004) The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22(1):19-22
6. Forastiere AA, Trotti A, Pfister DG, Grandis JR (2006) Head and neck cancer: recent advances and new standards of care. J Clin Oncol 24(17):2603-2605
7. Staar S, Rudat V, Stuetzer H et al (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multcentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161-1171
8. Adelstein D, Saxton J, Lavertu P et al (1997) A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy aline in resectable stage III and IV squamous cell head and neck cancer: preliminary results, chemoradiotherapy vs. radiotherapy. Head Neck 19:567-575
9. Adelstein DJ, Leblanc M (2006) Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 24(17):2624-2628
10. Brasnu DF, Hartl DM (2008) The Laryngologist in organ preservation for laryngeal cancer, letter to the editor. Laryngoscope 118(4):759-760
11. Webb S, Hartmann G, Echner G, Schlegel W (2003) Intensity-modulated radiation therapy using a variable-aperture collimator. Phys Med Biol 48(9):1223-1238
12. Robbins KT, Kumar P, Harris J, McCulloch T, Cmelak A, Sofferman R, Levine P, Weisman R, Wilson W, Weymuller E, Fu K (2005) Supradose intra-arterial cisplatin, concurrent radiation therapy for the treatment of stage IV head, neck squamous cell carcinoma is feasible, efficacious in a multi-institutional setting: results of radiation therapy oncology group trial 9615. J Clin Oncol 23(7):1447-1454
13. Mimeault M, Hauke R, Mehta PP, Batra SK (2007) Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11(5):981-1011
14. Guide to targeted therapy drugs in the pipeline. http://www.hemonctoday. com
15. Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A (2008) Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 30(5):667-674
16. Molinolo AA, Hewitt SM, Amornphimoltham P et al (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964-4973
17. Barnes CJ, Ohshiro K, Rayala SK et al (2007) Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13:4291-4299
18. Lin DT, Subbaramaiah K, Shah JP et al (2002) Cyclooxygenase-2: a novel molecular target for the prevention, treatment of head, neck cancer. Head Neck 24(8):792-799
19. Kawakami M, Kawakami K, Puri RK (2003) Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways. Int J Cancer 103(1):45-52
20. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90(11):824-832
21. Ritter CA, Arteaga CL (2003) The epidermal growth factor receptor-tyrosine kinase: promising therapeutic target in solid tumors. Semin Oncol 30:3-11
22. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20(Suppl 18):1s-13s
23. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567-578
24. Khazaeli MB, LoBuglio AF, Falcey JW, Paulter V, Fetzer M, Waksal H (2000) Low immunogenicity of a chimeric monoclonal antibody (MAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. Proc Am Soc Clin Oncol (abstr. no. 808)
25. Robert F, Ezekiel MP, Spencer SA et al (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19(13):3234-3243
26. Argiris A, Karamouzis MV, Heron DE, Smith R, Ferris R, Lai S, Kim S, Branstetter B, Johnson J, Grandis J (2007) Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2007 ASCO Annual Meeting 25(18S):6051
27. Vermorken J, Mesia R, Vega V, Remenar E, Hitt R, Kawecki A, Rottey S, Amellal N, Cupissol D, Licitra L (2007) Cetuximab extends survival of patients with recurrent or metastatic HNSCC when added to first line platinum based therapy-results of a randomized phase III (EXTREME) study. ASCO 2007 (abstr. no. 6091)
28. Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18(1):7-15
29. Wirth LJ, Posner MR, Tishler RB, Haddad RI, Goguen L, Clark JR, Allen AM (2007) Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results. J Clin Oncol 2007 ASCO Annual Meeting 25(18S):6083
30. Kim ES, Mauer AM, Tran HT et al (2003) A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc Am Soc Clin Oncol 22 (abstr. no. 2581)
31. Bourhis J, Rivera F, Mesia R et al (2006) Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24:2866-2872
32. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16):2171-2177
33. Pfister DG, Su YB, Kraus DH et al (2006) Concurrent cetuximab, cisplatin, concomitant boost radiotherapy for locoregionally advanced, squamous cell head, neck cancer a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24:1072-1078
34. Merlano MC, Numico G, Russi EG, Benasso M, Colantonio I, Vigna Taglianti R, Lanzilotta L, Vigo V, Bacigalup A (2007) Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): A phase II study. J Clin Oncol 2007 ASCO Annual Meeting 25(18S):6043
35. Ang KK (2008) A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) [followed by surgery for selected patients] for stage III and IV head and neck carcinomas 2008. Clinical trials.gov.NCT00265941; CDR0000458049, RTOG-0522
36. ®), 5 Fluorouracil, hydroxyurea, and twice-daily radiation (CetuxFHX) versus cetuximab (ERBITUX®), cisplatin, and accelerated radiation with concomitant boost (CetuxPX) after induction chemotherapy in patients with locally advanced head and neck cancer2007. Clinical trials.gov, NCT00468169
37. Melichar B, Cerman J Jr, Malírová E (2007) Successful management of infusion reaction accompanying the start of cetuximab therapy. Support Care Cancer 15(4):445-449
38. Budach W, Bölke E, Homey B (2007) Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357(5):514-515
39. Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803-811
40. Lefebvre JL (2006) Larynx preservation with induction chemotherapy (cisplatin, 5FU, docetaxel) followed by radiotherapy combined with either cisplatin or cetuximab in laryngopharyngeal squamous cell carcinoma-a randomised phase II study, GORTEC. Clinical trials.gov, NCT00169247
41. Dietz A (2007) DeLOS-II; randomised phase II screeningstudy to be used in an TPF-chemotherapy (shortinduction) before TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/hypopharynx. EudraCT-Nr.: 2006-006091-38. Clinical trials.gov, NCT00508664
42. Le Tourneau C, Siu LL (2008) Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 20(3):256-263
43. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (Epub ahead of print)
44. A randomised, double-blind, placebo-controlled, multi-centre, phase III study of post-operative adjuvant lapatinib or placebo and concurrent chemoradiotherapy followed by maintenance lapatinib or placebo monotherapy in high-risk subjects with resected squamous cell carcinoma of the head and neck (HNSCC); GlaxoSmithKline, EGF102988. Clinical trials.gov, NCT00424255
45. Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KL (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol (Epub ahead of print)
46. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20(21):4292-4302
47. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139
48. Mazitschek R, Giannis A (2004) Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. Curr Opin Chem Biol 8:432-441
49. Ropert S, Mir O, Armand JP (2007) Oral drugs inhibiting the VEGF pathway. Bull Cancer 94(Spec No):S180-90.
50. Xiao X, Wu J, Zhu X, Zhao P, Zhou J, Liu QQ, Zheng L, Zeng M, Liu R, Huang W (2007) Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 121(9):2095-2104
51. Sano D, Kawakami M, Fujita K, Kimura M, Yamashita Y, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M (2007) Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 17(2):289-295
52. Rodrigo JP, Cabanillas R, Secades P, Canel M, Chiara MD, Suárez C (2007) Relationship between FAK and P53 expression in squamous cell carcinomas of the larynx. Acta Otorrinolaringol Esp 58(8):347-351
53. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN (2007) A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 46(6):488-496
54. Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M (2001) Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85(5):649-655
55. Curtin NJ, Hughes AN (2001) Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol 2(5):298-306
56. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M (2001) Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85(5):649-655
57. Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G (2008) Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 26(7):1135-1141
58. Hanauske AR, Oberschmidt O, Hanauske-Abel H, Lahn MM, Eismann U (2007) Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments. Invest New Drugs 25(3):205-210
59. Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hanauske-Abel HM, Blatter J, Ma D, Chen V, Lahn M (2007) Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells. Invest New Drugs (Epub ahead of print)
60. Green MR (2004) Targeting targeted therapy. N Engl J Med 350(21):2191-2193
61. Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM (2007) Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg 133(10):1022-1027
62. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104(3):973-978
63. Boldrup L, Coates PJ, Gu X, Nylander K (2007) DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol 213(4):384-391